Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 DiabetesGlobeNewsWire • 12/17/24
Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)GlobeNewsWire • 12/16/24
Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)GlobeNewsWire • 12/12/24
Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute LeukemiaGlobeNewsWire • 12/09/24
Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute LeukemiaGlobeNewsWire • 12/06/24
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 12/02/24
The Schall Law Firm Urges Shareholders With Losses To Join An Inquiry Into Biomea Fusion, Inc. For Securities Law ViolationsAccesswire • 11/04/24
Biomea Fusion Inc Is Being Investigated For Securities Fraud And Affected Investors Are Encouraged To Contact The Schall Law FirmAccesswire • 11/03/24
The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Biomea Fusion, Inc. For Securities Law ViolationsAccesswire • 11/02/24
Biomea Fusion Inc Is Being Investigated For Fraud And Investors With Losses Are Encouraged To Contact The Schall Law FirmAccesswire • 10/31/24
Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist CandidateGlobeNewsWire • 10/30/24
The Schall Law Firm Urges Stockholders To Help With An Inquiry Into Biomea Fusion, Inc. For Securities Law ViolationsAccesswire • 10/30/24
Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate HighlightsGlobeNewsWire • 10/29/24
An Investigation Has Been Launched Into Whether Biomea Fusion Inc Committed Fraud And Investors With Losses Are Encouraged To Contact The Schall Law FirmAccesswire • 10/29/24
The Schall Law Firm Urges Shareholders To Take Part In An Inquiry Into Biomea Fusion, Inc. For FraudAccesswire • 10/28/24
The Schall Law Firm Urges Shareholders To Join An Inquiry Into Biomea Fusion, Inc. For Securities Law ViolationsAccesswire • 10/27/24
Biomea Fusion Inc Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law FirmAccesswire • 10/26/24
Biomea Fusion Inc Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Reach Out To The Schall Law FirmAccesswire • 10/22/24
Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219GlobeNewsWire • 10/21/24
Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law FirmAccesswire • 10/20/24
The Schall Law Firm Urges Shareholders To Join An Inquiry Into Biomea Fusion, Inc. For Securities Related InfractionsAccesswire • 10/19/24
Biomea Fusion Inc Is Being Investigated For Possible Securities Fraud And Affected Investors Are Encouraged To Contact The Schall Law FirmAccesswire • 10/18/24
The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Biomea Fusion, Inc. For Securities Related InfractionsAccesswire • 10/17/24
Biomea Fusion, Inc. (BMEA) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their RightsAccesswire • 10/16/24
